Table 1. Phase III studies comparing gefitinib or erlotinib versus a standard platinum-based doublet in the first line treatment of advanced NSCLC patients selected based on the presence of EGFR mutation.

Study	EGFR-TKI	No. of patients	Type of EGFR mutation	Population	RR (EGFR-TKI vs. chemotherapy)	PFS (EGFR-TKI vs. chemotherapy)	OS (EGFR-TKI vs. chemotherapy)	Quality of life (EGFR-TKI vs. chemotherapy)
WJTOG 3405 (19)	Gefitinib	172	del19 or L858R	Asiatic	62.1% vs.32.2%† P<0.0001	9.2 vs. 6.3 months P<0.0001	Not available	Not assessed
NEJ002 (20,34)	Gefitinib	228	Any‡	Asiatic	73.7% vs. 30.7% P<0.001	10.4 vs. 5.5 months P<0.001	30.5 vs. 23.6 months P=0.31	Significant less deterioration§
OPTIMAL (21)	Erlotinib	154	del19 or L858R	Asiatic	83% vs. 36% P<0.0001	13.1 vs. 4.6 months P<0.0001	Not available	Significant improvement¶
EURTAC (22)	Erlotinib	173	del19 or L858R	Caucasian	58% vs. 15% P<0.05	9.7 vs. 5.2 months P<0.0001	Not available	Not available

EGFR-TKI, epidermal growth factor receptor-tyrosine kinase inhibitor; No., number; OS, overall survival; PFS, progression-free survival; RR, response rare. ^†Only patients with measurable disease considered. ^‡Excluded the T790M resistant mutation. ^§As assessed by a Care Notebook (QOL Res 2005, http://homepage3.nifty.com/care-notebook/) questionnaire. ^¶As assessed with the Functional Assessment of Cancer Therapy-Lung (FACT-L) questionnaire and the Lung Cancer Subscale (LCS).